Leridistim
Also known as: MGDF/G-CSF chimera, myeloid progenitor stimulator
Source Leridistim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Leridistim is an investigational chimeric cytokine designed to stimulate multilineage hematopoietic recovery, combining activities targeting G-CSF and IL-3 receptor pathways. It was studied in clinical trials for the treatment of chemotherapy-induced neutropenia and thrombocytopenia, particularly in patients undergoing myelosuppressive chemotherapy or bone marrow transplantation. Development was discontinued and it never received regulatory approval.
Mechanism of Action
Leridistim is a chimeric protein that simultaneously activates both the myeloid progenitor inhibitory factor-1 (MPIF-1/CCL23) receptor and the granulocyte colony-stimulating factor receptor (G-CSF-R), promoting hematopoietic progenitor cell expansion and neutrophil production while also activating the interleukin-3 receptor (IL-3R) pathway, thereby stimulating multilineage hematopoiesis.
Routes of Administration
Goals & Uses
- Multilineage hematopoietic recovery post-bone marrow transplantHematopoiesisLow
- Platelet recovery after chemotherapyHematopoiesisModerate
- Neutrophil recovery after chemotherapyHematopoiesisModerate
- Reduction of infection risk during myelosuppressionSupportive Oncology CareLow
Contraindications
- Known hypersensitivity to leridistim or related cytokinesAllergy/ImmunologyHigh
- Active malignant myeloid disease (e.g., AML, CML)OncologyHigh
Adverse Effects
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Fever/flu-like symptomsSystemicCommon
- SplenomegalyHematologicUncommon
Drug Interactions
- Other colony-stimulating factors (G-CSF, GM-CSF)Moderate
- Myelosuppressive chemotherapy agentsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with pre-existing autoimmune conditionsImmunologicRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval sought or granted; development discontinued before submission.
- United StatesInvestigationalStudied in Phase II/III trials but never approved by the FDA. Development discontinued.
Never received FDA, EMA, or other regulatory approval. Development was discontinued following clinical trials in the late 1990s and early 2000s. Investigated primarily by Immunex Corporation.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Leridistim?
Leridistim is an investigational chimeric cytokine designed to stimulate multilineage hematopoietic recovery, combining activities targeting G-CSF and IL-3 receptor pathways. It was studied in clinical trials for the treatment of chemotherapy-induced neutropenia and thrombocytopenia, particularly in patients undergoing myelosuppressive chemotherapy or bone marrow transplantation. Development was discontinued and it never received regulatory approval.
What is Leridistim used for?
Leridistim is educationally associated with: Multilineage hematopoietic recovery post-bone marrow transplant, Platelet recovery after chemotherapy, Neutrophil recovery after chemotherapy, Reduction of infection risk during myelosuppression. Educational only — not medical advice.
How is Leridistim administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Leridistim?
Reported adverse effects include: Bone pain, Injection site reactions, Headache, Fever/flu-like symptoms, Splenomegaly. This list is not exhaustive — consult a qualified clinician.
Who should avoid Leridistim?
Recorded contraindications: Known hypersensitivity to leridistim or related cytokines, Active malignant myeloid disease (e.g., AML, CML). Consult a qualified clinician before use.